XORTX Therapeutics (XRTX) Accounts Payables (2020 - 2026)

XORTX Therapeutics (XRTX) has 7 years of Accounts Payables data on file, last reported at $844932.0 in Q1 2026.

• Quarterly Accounts Payables rose 103.26% year-over-year to $844932.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $844932.0 (up 103.26% YoY) and the FY2025 annual result came in at $553784.0, up 276.2% from the prior year.
• Accounts Payables grew to $844932.0 in Q1 2026, from $553784.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.4 million in Q4 2022 to a low of $147205.0 in Q4 2024.
• A 5-year average of $596758.5 and a median of $525245.0 in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables slumped 80.38% — and 2025, when it jumped 276.2%.
• Tracing XRTX's Accounts Payables over 5 years: stood at $1.4 million in 2022, then tumbled by 80.38% to $283428.0 in 2023, then tumbled by 48.06% to $147205.0 in 2024, then jumped by 276.2% to $553784.0 in 2025, then surged by 52.57% to $844932.0 in 2026.
• The last three Accounts Payables figures came in at $844932.0 (Q1 2026), $553784.0 (Q4 2025), and $677314.0 (Q3 2025), per Business Quant data.